PIN120 Patients with Chronic Hepatitis C Virus Treated with Simeprevir Added to Peginterferon and Ribavirin Experienced Less Time with Fatigue, Depressive Symptoms, and Functional Limitations: Results from Patients in the Quest-1, Quest-2, and Promise Studies  by Scott, J. et al.
A362  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
PIN121
PaPer-Based aNd electroNIc assessmeNt of HealtH-related QualIty 
of lIfe sPecIfIc to HIV dIsease: a relIaBIlIty study wItH tHe ProQol-
HIV QuestIoNNaIre
Lalanne C.1, Herrmann S.2, Armstrong A.R.3, Cheung-Lung C.3, Schwartz Y.4, Chassany O.5, 
Duracinsky M.6
1AP-HP, Paris, France, 2Murdoch University, Perth, Western Australi, Australia, 3Assistance 
Publique-Hopitaux de Paris, Paris, France, 4Inria Saclay-Ile de France, Gif sur Yvette, France, 
5University Paris 7, Paris, France, 6Hospital Kremlin Bicetre, Paris, Ile de France, France
Objectives: Electronic Patient Reported Outcomes (PRO) provide quick and reli-
able assessment of patients’ health-related quality of life (HRQL). An electronic 
version of the PROQOL-HIV questionnaire was developed, and its face validity 
and reliability were assessed using standard psychometric methods. MethOds: 
A total of 70 French outpatients (63% males, mean age 47 years) were recruited. 
Hard copy and electronic questionnaires were completed in a randomized cross-
over design (2-7 day interval). Biomedical data were collected. Questionnaire ver-
sion and order effects were tested on full scale scores in a two-way ANOVA with 
patients as random effects. Test-retest reliability was evaluated using Pearson and 
intra-class correlation coefficients (with 95% confidence interval) for each dimen-
sion. Usability testing was carried out from patients’ survey reports, specifically: 
general satisfaction, ease of completion, quality and clarity of user interface (UI) 
and self motivation for electronic measuring to monitor HRQL in clinical follow-
up. Results: Questionnaire version and administration order effects (N= 58 
complete cases) were not significant at the 5% level, nor interacting together 
(p= 0.940). Reliability indices were acceptable, with Pearson correlations above 
0.7 and intra-class correlations ranging from 0.696 to 0.926, and scores were not 
statistically different between the two versions. On 77% of complete surveys, 57% 
of patients reported being satisfied and interested in electronic assessment of 
their HRQL in clinical follow up. Individual ratings of PROQOL-HIV user interface 
(85-100% of positive responses) confirmed UI clarity and usability. cOnclusiOns: 
The electronic PROQOL-HIV introduces minor modifications compared to the 
original paper-based version, following ISPOR ePRO Task Force guidelines, and 
it showed good reliability and face validity. Patients can complete the computer-
ized PROQOL-HIV questionnaire as intended and scores delivered from paper or 
electronic version share comparable accuracy and interpretation.
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Objectives: The immunization is currently one of the most discussed topics in 
the population and the number of its opponents is increasing. MethOds: Opinion, 
awareness and knowledge of parents (n-parents= 240, n-children= 463) about child-
hood immunization through self-reported technique of a questionnaire survey was 
conducted, with respect of gender, age, education and profession of parents in 
regard of their professional connection with health care in case of obligatory and 
recommended childhood vaccination. Results: In case of obligatory childhood 
vaccination all evaluated parameters influence and change opinion, awareness 
and knowledge of parents. Age (p< 0,01, Degree of freedom (df)= 10, Chi-squared 
distribution (χ ²)= 81,08, table value of Chi-squared distribution (tχ ²)= 23,21); gender 
(p< 0,01, df= 2, χ ²= 12,87, tχ ²= 9,21); education (p< 0,01, df= 10, χ ²= 79,11, tχ ²= 23,21); 
health care profession (p< 0,01, df= 2, χ ²= 13,75, tχ ²= 9,21. In case of recommended 
childhood vaccination all analyzed parameters influence and change parents’ 
opinion, awareness and knowledge, except for those working in health care. Age 
(p< 0,01, df= 5, χ ²= 13,29, tχ ²= 15,09); gender (p< 0,01, df= , χ ²= 79,82, tχ ²= 13,28); educa-
tion (p< 0,01, df= 4, χ ²= 49,10, tχ ²= 13,28); health care profession (0,01< p< 0,03, df= 1, 
χ ²= 4,85, tχ ²= 6,64). cOnclusiOns: Analysis confirms that age, gender, education 
and profession connected with health care influence and change parents’ opinion, 
awareness and knowledge about obligatory childhood vaccination. Regarding the 
recommended childhood vaccination, age, gender and education influence and 
change parents’ opinion, awareness and knowledge, although a profession con-
nected with health care neither influences, nor changes opinion, awareness and 
knowledge of the parents.
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Objectives: Both chronic HCV infection and current treatments negatively impact 
patient reported outcomes. PegIFN/RBV-based therapies decrease general HRQoL 
scores 10%-30% (on SF-36). Psychometric analyses of validity, responsiveness, 
and MID for the HCV-specific HCV-PRO instrument were performed. MethOds: 
Responses to the HCV-PRO (presented ILC2012), the SF-36, and EuroQol-5D 
(EQ-5D)+VAS were analyzed in the M11-602 trial of pegIFN/RBV with placebo 
(n= 11) or DAA: ABT-450/ ritonavir (n= 24), ABT-072 (n= 23), or ABT-333 (n= 16). 
DAAs were administered for 12 weeks, pegIFN/RBV for 48 weeks. PRO instru-
ments were administered at baseline, week 8, end of DAA treatment (EODT), end 
of pegIFN/RBV treatment (EOT), and posttreatment week 24 (PT24). Convergent 
validity of HCV-PRO total score (range 0-100) was assessed through correlation 
(Pearson’s) to SF-36 MCS/PCS and EQ-5D VAS scores. Discriminant validity was 
assessed by dichotomizing HCV-PRO responses on EQ-5D Anxiety/Depression 
dimension severity (none vs. some) and treatment emergent depression/fatigue 
adverse events (MedDRA terms). Responsiveness was assessed through analyses 
of effect size (ES). MID was assessed by standard error of the mean (SEM) and 
The initial step involved undertaking a review of published literature detail-
ing HIV patients’ experiences of receiving ARV therapy. These findings formed 
the basis of a meeting of leading European HIV clinical experts, prominent HIV 
organisation representatives and patients themselves. Results: The literature 
revealed numerous factors such as convenience, tolerability, relationship with 
physician and disease characteristics which influences patients’ satisfaction 
with treatment. Discussion between the clinicians, representative from patient 
organisations emphasised the importance of patient preferences as they relate 
to adherence with HIV therapy. This additional insight emphasised the under-
recognised role played by individual differences and therapeutic knowledge 
in defining attitudes to treatments. cOnclusiOns: Treatment satisfaction is 
a complex issue. The work undertaken so far has highlighted that despite the 
advances in ARVs there are still concerns for PLWH. The next stage of research 
involves undertaking a series of in-depth qualitative interviews with patients 
across Europe and examining attributes of HIV treatment using the discrete 
choice experiment methodology.
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Objectives: To determine parental preferences concerning rotavirus vaccination 
for their newborn baby, and to calculate the potential vaccination coverage for dif-
ferent vaccine scenarios. MethOds: A Discrete Choice Experiment (DCE) question-
naire was sent to the parents of 1,250 newborns aged 6 weeks in The Netherlands. 
The DCE included nine D-efficient designed choice tasks. Panel-mixed-logit models 
were used to estimate the relative importance of the five included rotavirus vaccine 
attributes; vaccine effectiveness, frequency of severe side effects, protection dura-
tion, location of vaccine administration, out-of-pocket costs. The potential uptake 
or vaccine coverage was calculated for different vaccine scenarios. Results: All 
attributes showed a significant estimate (P< .05). Parents were more likely to get 
their newborn vaccinated if the vaccine effectiveness increased, parents preferred 
a frequency of 1 in 1,000,000 children that suffer from severe side effects over a 
frequency of 1 in 10,000. Protection duration of 3 years was preferred over 1 year 
and parents preferred to get their child vaccinated at the GP’s office. Finally, increas-
ing out-of-pocket costs were associated with decreased willingness to vaccinate. 
With respect to the relative importance of these attributes, vaccine effectiveness 
was most decisive for parents, followed by out-of-pocket costs, protection duration 
and frequency of severe side effects. Vaccination coverage rates ranged between 
22.8% for the least preferred vaccine scenario and 87.5% for the most preferred 
scenario. cOnclusiOns: When deciding whether to vaccinate their newborn baby 
against the rotavirus, parents are mostly driven by the effectiveness of the vaccine, 
the out-of-pocket costs, protection duration and the frequency of severe side effects. 
Differences in vaccine scenarios resulted in a large range in expected vaccination 
coverage. Therefore, the context and content of the implementation strategy of the 
vaccination is expected to strongly affect the vaccination coverage. Specifically 
requesting an out-of-pocket payment of parents should be considered carefully if 
a high vaccine coverage is desired.
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Objectives: To examine the value of adding simeprevir (SMV) to peginterferon 
and ribavirin (PR) for treatment of chronic hepatitis C virus infection using patient-
reported outcomes (PRO) and their concordance with virology endpoints and 
adverse events (AEs). MethOds: Patients rated severity of fatigue (FSS), depres-
sive symptoms (CES-D), and impairment in functioning (WPAI:HepC Productivity, 
Activity, Absenteeism) at baseline and throughout treatment/follow-up in three 
randomized, double-blind trials comparing addition of SMV or Placebo (PBO) dur-
ing initial 12 weeks of PR treatment. PR was administered for 48 weeks (PBO group) 
and either 24 or 48 weeks (SMV group) (response-guided therapy [RGT]). Analysis 
of pooled data from the trials using a piecewise-linear mixed model compared 
the area-under-the-curve from baseline to Wk60 (AUC60) between SMV/PR and 
PBO/PR for each PRO score. Subgroup analyses evaluated impact of Sustained 
Virologic Response 12 weeks post-treatment (SVR12), fibrosis level, and RGT on 
PRO scores. Results: Of 1178 patients studied, analyses included 768 SMV/PR- and 
393 PBO/PR-treated patients. 87.5% of the SMV/PR group met RGT and completed 
treatment in 24 weeks. Fatigue and anaemia AEs were comparable in both groups but 
FSS scores show clinically important increases in fatigue, lasting 6.9 weeks longer 
with PBO/PR (p < 0.001). No significant differences were observed for Absenteeism. 
Mean scores for all other PRO endpoints worsened from baseline to Wk4 in both 
groups and remained impaired to Wk24 (SMV/PR) and Wk48 (PBO/PR), resulting 
in significantly lower AUC60and fewer weeks with clinically important worsening 
scores with SMV/PR. PRO scores indicated better outcomes for patients who met RGT 
criteria or achieved SVR12; differences in PRO scores associated with fibrosis level 
were only observed in the PBO/PR group. cOnclusiOns: Greater efficacy of SMV/
PR enabled reduced treatment duration and less time with PR-related side effects 
without adding to the severity of side-effects during treatment.
